Vidarabine (also known as adenine arabinoside and ara-A) is a nucleoside antibiotic isolated from Streptomyces antibioticus. Vidarabine is indicated for the treatment of recurrent epithelial keratitis and acute keratoconjunctivitis due to herpes simplex virus (HSV) types l and 2. It is also effective in superficial keratitis caused by HSV which has not responded to topical idoxuridine or when toxic or hypersensitivity reactions due to idoxuridine have occurred. It is also indicated for the treatment of infections caused by a variety of viruses such as the herpes viruses, the vaccinia virus, and varicella zoster virus (VZV) (chickenpox).
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Vidarabine, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.